Market Overview

Analyst: Why Humana And Walmart Could Make Sense Together

Analyst: Why Humana And Walmart Could Make Sense Together
Related HUM
Benzinga's Top Upgrades, Downgrades For January 11, 2019
How 7 New Laws Affected Stocks In The Last Week
New medical chief at Humana (Seeking Alpha)
Related WMT
Raymond James: CVS A Strong Buy Despite Pricing Headwinds
Shoe Retailer DSW To Sell Green Growth Brands' CBD Products
Risk-Reward With Macy's (GuruFocus)

Retail giant Walmart Inc (NYSE: WMT) is reportedly in early discussions with Humana Inc (NYSE: HUM) that include the possibility of an outright acquisition, The Wall Street Journal reported.

The Analyst

Stifel's Mark Astrachan maintains a Hold rating on Walmart's stock with an unchanged $99 price target.

The Thesis

The strategic merits of a potential deal include the following, Astrachan said:

  • The addition of new customer data could be additive to store traffic and help Walmart learn more about the health care industry. Cost savings, particularly for health care products and services.
  • The ability for Walmart to sustain heightened investment levels.
  • A "proactive response" to Amazon's potential entry into the health care services.

A Humana deal could be approximately 3-to-4-percent accretive to Walmart's earnings per share, the analyst said. (See Astrachan's track record here.) 

"That said, a potential transaction would also meaningfully increase the complexity of Walmart's business, including adding a heavily regulated entity that derives 79 percent of premium and services revenue from contracts with the U.S. government," Astrachan said. 

Walmart and Humana have an existing relationship through their co-branded prescription drug offering, the analyst said. If an acquisition isn't realized, the two companies can still expand their relationship — in a manner similar to CVS' strategy of expanding in-store medical clinics for basic services — which in turn will drive incremental traffic into Walmart stores, according to Stifel. 

Price Action

Shares of Humana were trading higher by 6.2 percent at the time of publication Monday. Amazon shares were down 3.7 percent. 

Related Links:

Leerink's Takeaways From CNBC's 'Healthy Returns' Conference

Cramer: Here's Why Centene Is A Buy Amid Amazon's Health Care Push

Latest Ratings for HUM

Jan 2019Stephens & Co.Initiates Coverage OnOverweight
Jan 2019Cowen & Co.UpgradesMarket PerformOutperform
Dec 2018JP MorganUpgradesNeutralOverweight

View More Analyst Ratings for HUM
View the Latest Analyst Ratings

Posted-In: Analyst Color News Health Care Price Target Reiteration M&A Top Stories Analyst Ratings Best of Benzinga


Related Articles (HUM + WMT)

View Comments and Join the Discussion!

Latest Ratings

EMNMorgan StanleyUpgrades90.0
DERMRaymond JamesUpgrades0.0
View the Latest Analytics Ratings
Don't Miss Out!
Join Our Newsletter
Subscribe to:
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Fintech Focus
Your weekly roundup of hot topics in the exciting world of fintech.
Thank You
for registering for Benzinga’s newsletters and alerts.
• The Daily Analysts Ratings email will be received daily between 7am and 10am.
• The Market in 5 Minutes email will be received daily between 7am and 8am.
• The Fintech Focus email will be received every Friday between 2pm and 5pm.

AMD, Nvidia Cut GPU Prices As Crypto Slump Saps Demand

Mid-Morning Market Update: Markets Open Lower; Cal-Maine Foods Posts Upbeat Sales